Laboratorio Clinico Jaimar Ii

Summary Statement of Deficiencies D5791 ANALYTIC SYSTEMS QUALITY ASSESSMENT CFR(s): 493.1289(a)(c) (a) The laboratory must establish and follow written policies and procedures for an ongoing mechanism to monitor, assess, and when indicated, correct problems identified in the analytic systems specified in 493.1251 through 493.1283. This STANDARD is not met as evidenced by: 1. Based on quality assessment (QA) program review (years 2025-2026) and laboratory director interview on March 27, 2026 at 10:00 A.M. , the laboratory failed to follow the established QA Program to monitor and evaluate the following requirements for analytic systems: comparison of test results. The findings include: a. On March 27, 2026 at 10:00 A. M, a review of the laboratory established QA program showed that the laboratory must evaluate, twice a year , ten (10) patient results that appear inconsistent with the following relevant criteria, when available: patient age, Sex, diagnosis, relationship with other test parameters. b. The records showed that the laboratory performed the last evaluation on June 2024. c. The laboratory director confirmed during the interview on March 26, 2026 at 10:00 AM, that the laboratory failed to follow the established QA evaluations since June 2024. 2. Based on quality assessment (QA) program review (years 2025-2026) and laboratory director interview on March 27, 2026 at 10:00 A.M. , the laboratory failed to follow the established QA Program to monitor and evaluate the following requirements for analytic systems: comparison of test results. The findings include: a. On March 27, 2026 at 10:00 A. M, a review of the laboratory established QA program showed that the laboratory must evaluate, twice a year , ten (10) patient results that appear inconsistent with the following relevant criteria, when available: patient age, Sex, diagnosis, relationship with other test parameters. b. The records showed that the laboratory performed the Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- last evaluation on June 2024. c. The laboratory director confirmed during the interview on March 26, 2026 at 10:00 AM, that the laboratory failed to follow the established QA evaluations since June 2024. D6093 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(e)(5) (e)(5) Ensure that the quality control and quality assessment programs are established and maintained to assure the quality of laboratory services provided and to identify failures in quality as they occur; This STANDARD is not met as evidenced by: Based on quality assessment (QA) review (years 2025-2026) and laboratory director interview on March 27, 2026 at 11:30 A.M., the laboratory director failed to ensure compliance with the quality assessment program. Refer to D5791. -- 2 of 2 --

Summary Statement of Deficiencies D5014 GENERAL IMMUNOLOGY CFR(s): 493.1208 If the laboratory provides services in the subspecialty of General immunology, the laboratory must meet the requirements specified in 493.1230 through 493.1256, and 493.1281 through 493.1299. This CONDITION is not met as evidenced by: Based on Mycoplasma pneumoniae test quality control records and patient records review ( year 2022 ) and interview with the laboratory director on November 17, 2022 at 9:00 A.M., it was determined that the laboratory failed to meet the requirements in the subspecialty of General Immunology. The finding includes: 1. The laboratory did not include an external positive and a negative control material each day of patient testing. Refer to D5449 D5449 CONTROL PROCEDURES CFR(s): 493.1256(d)(3)(ii)(g) Unless CMS Approves a procedure, specified in Appendix C of the State Operations Manual (CMS Pub. 7), that provides equivalent quality testing, the laboratory must-- At least once a day patient specimens are assayed or examined perform the following for-- Each qualitative procedure, include a negative and positive control material; (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Based on General Immunology (Mycoplasma pneumoniae test) quality control records review (years 2022) and laboratory director interview, it was determined that the laboratory did not include an external positive and negative control material each Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- day of Mycoplasma pneumoniae patient testing. The findings include: 1. The laboratory performed Mycoplasma Pneumoniae test by Immuno Card method. 2. General Immunology (Mycoplasma pneumoniae test) quality control records were review on November 17, 2022 at 9:00 A.M., from September 21, 2022 to November 16, 2022. 3. Review of Mycoplasma pneumoniae quality control and patient results record showed that the laboratory did not include any control material each day of patient testing since September 21, 2022 . ( review on November 17, 2022 at 9:05 a. m. ) 4. The laboratory director confirmed on November 17, 2022 at 9:10 A.M, that the laboratory failed to include a negative and positive control material each day of testing when performed Mycoplasma pneumonia test. 5. The laboratory did not include any control material, when 35 out 35 patient specimen were processed and since September 21, 2022 . ( review on November 17, 2022 at 9:05 a.m. ) D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on Mycoplasma pneumoniae quality control records review ( year 2022 ) and laboratory director interview on November 17, 2022 at 9:20 A.M, it was determined that the laboratory director failed to fulfill his responsibilities and duties to ensure compliance with the laboratory analytical system requirements. The finding includes: 1. The laboratory director did not comply with the requirement for analytical systems requirements. Refer to D 6020. D6020 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(5) The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(5) Ensure that the quality control program is established and maintained to assure the quality of laboratory services provided. This STANDARD is not met as evidenced by: Based on Mycoplasma pneumoniae testing records review ( year 2022 ) and laboratory director interview on November 17, 2022 at 9:20 a.m. , it was determined that the laboratory director failed to ensure that the laboratory follow to ensure compliance with the requirements for analytic systems. Refer to D5449. -- 2 of 2 --